Colorectal Cancer Stage II and III Cancer Hospital Dharmais Got Adjuvant Chemotherapy
ABSTRACT: Background: Colorectal Cancer is the 6th most common malignancy found at Dharmais Cancer Hospital. Adjuvant chemoradiation post tumor resection is given to CCR stage II and III. Many factors are considered to determine the survival rate of the colorectal cancers patient such as gene p53, K-ras, DNA content and SPF. Objective: To discover the relationship between the K-ras and p53 gene with the DNA and the survival rate in patients with stage II and II coloractal cancers and its correlation with the K-ras gene and p53 gene mutations receiving adjuvant therapy after resections. Method: This was a restropective cohort study completed at Dharmais Cancer Hospital. Bivariate and multivariate analysis was performed to discover the relationships between variables. The survival rate was analyzed using the Kaplan-Meier method and the overall survival log hypothesis of the statistically significant variables used the Proportional Hazard (Cox) Regression. Results: 42 block paraffin samples were included in this study. We discovered that there were p53 gene mutations in the 247 codon exxon 6. The relationship between variables is described with the following formula: H(t,x)= ho(t) exp [-0,194(K-ras) - 6,379(p53) - 0,72 (DNA) - 25,797 (SPF) + 6,993 (Stage) - 0,947(Moderate differentiated) - 2,952 (Poorly differentiated). Conclusions: We concluded that the K-ras and p53 gene was not strongly correlated with DNA and SPF. The survival rate was higher in patients with aneuploid DNA, abnormal SPF, and p53 gene mutations.
